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1(5) days; p < 0.005). QQ and WPAI-GH scores were highly
correlated (r = 0.64). The inﬂuence of health problems on work
productivity on the last 7 days differed signiﬁcantly (p < 0.001)
between patients (2.3  2.5) and controls (0.5  1.2). CON-
CLUSIONS: This study indicates that the impact of RA not only
leads to productivity loss due to an increase in time missed from
work (absenteeism), but also due to an impaired performance at
work (presenteeism).
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OBJECTIVES: The objective of this study was to do a cost-
effectiveness analysis of inﬂiximab for the treatment of rheuma-
toid arthritis (RA) in Swedish clinical practice, based on data
from the STURE (Stockholm TNF-alpha follow-up registry).
METHODS: Real world data from the STURE registry was
implemented in a Markov cohort model, in which health states of
disease severity were classiﬁed according to HAQ (ﬁve catego-
ries) and DAS28 (active or non-active disease). The transition
probabilities between HAQ and DAS states in the treatment arm
as well as discontinuation rates were based on data from the
registry on patients taking inﬂiximab as their ﬁrst-line biological
treatment. The data covered 637 patients with a mean follow up
of 5.1 years since initiating inﬂiximab therapy, giving a high
degree of external validity to the results. After discontinuation,
patients were assumed to revert to their baseline HAQ score and
resume the natural disease progression rate. The transition prob-
abilities in the comparator arm (no biologic treatment) were
based on published literature on natural HAQ progression. The
analysis had a societal perspective, i.e. all relevant costs were
included irrespective of who incurred them, and efﬁcacy was
measured in quality-adjusted life-years (QALYs). In base case,
patients were assumed to be 54 years at start of treatment and
were followed for 20 years. RESULTS: Inﬂiximab was associated
with an incremental gain in QALYs of 1.06 and an incremental
cost of SEK201 286 compared to natural progression, producing
an incremental cost-effectiveness ratio (ICER) of SEK190 431.
Sensitivity analyses of input parameters and model assumptions
produced ICERs in the range from SEK150 000 to SEK400 000.
CONCLUSIONS: The results indicated that it is cost-effective to
treat patients with inﬂiximab compared to no biologic treatment
in patients with RA in Sweden.
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OBJECTIVES: To investigate the beneﬁt of anti-TNF therapy on
physical and mental functioning via the short form-36 (SF-36)
quality of life (QOL) questionnaire in patients with rheumatoid
arthritis (RA). METHODS: All patients entered onto the bio-
logic database between November 2004 and November 2007
with a diagnosis of rheumatoid arthritis were retrospectively
analysed. A total of 241 patients were included in the compari-
son. Complete data was collected on 73 patients from this
sample to date. Each patient on attending the clinic completes an
SF-36 questionnaire at baseline and at 12 months post biologic
therapy. The Disease Activity Score 28 (DAS) CRP, which
included swollen and tender joint count, a global disease assess-
ment and a CRP(C Reactive Protein) value, is also recorded at
these time points. The results of the questionnaire were then
analysed and the norm-based SF-36 scoring system was used to
calculate the physical and mental component summary scores
(PCS, MCS). These results were then entered onto an excel
database and statistical analysis (Paired Sample T test and Pear-
son’s Correlation) was completed using SPSS version 14. DAS 28
(CRP) scores were also examined to identify any correlation
between disease activity and quality of life. RESULTS: Twenty-
two (30%) of these were male with a mean age of 56 years. The
mean duration of disease in this cohort was 14 years. Statistical
analysis was completed on the N = 73. There was an improve-
ment in QoL which was demonstrated by the statistically sig-
niﬁcant increase in PCS and MCS pre and post biologic therapy.
However there was a greater increase in the PCS compared to
the MCS. A signiﬁcant negative correlation was seen between
the post biologic PCS and DAS (CRP) although the correlation
was weak (r = -0.45) (p =< 0.0001). A signiﬁcant correlation
was not seen between the MCS and the DAS (CRP) post biologic
therapy (r = -0.114) (p = 0.366). CONCLUSIONS: There is a
signiﬁcant increase in PCS post biologic therapy in this patient
cohort. The values of both MCS and PCS return to normal
population (US) based values within 12 months of initiating
biologic therapy. The decrease in PCS and MCS seen here is
consistent with other rheumatic diseases such as psoriatic arthri-
tis and ankylosing spondylitis as has been demonstrated in a
recent study [1]. The ﬁndings of the present study indicate a
signiﬁcant beneﬁt to QOL of patients following initiation of
anti-TNF therapy. A larger cohort of patients would be required
to examine the correlation between disease activity (DAS 28)
and QOL (PCS and MCS). [1] Han C, Smolen J, Kavanaugh A
et al. The impact of inﬂiximab treatment on quality of life in
patients with inﬂammatory rheumatic diseases. Arthritis
Research and Therapy 2007;9:R103.
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OBJECTIVES: Biological treatments have been promising
advances for individuals with rheumatoid arthritis (RA). Poor
adherence and treatment discontinuation, however, may under-
mine therapeutic beneﬁts and raise concerns given the high costs of
these agents. Our aim was to perform a systematic review of the
methods used to measure adherence to biologics and to identify
previously reported biologic adherence rates among RA patients.
METHODS: A MEDLINE search was performed from 1995 to
2007 using the following search terms: adherence, compliance,
discontinuation, treatment retention, RA, and biologics (e.g.
inﬂiximab, etanercept and adalimumab). Additional studies were
obtained from references of the identiﬁed articles. Two study
investigators independently reviewed the articles to determine
relevant studies and extracted information such as study objective,
adherence measure, mode of measurement, and main ﬁndings in a
standardized form. RESULTS: Seven of 508 articles met the
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